熱門資訊> 正文
Avenue Therapeutics GAAP每股收益为15.40美元,低于24.40美元
2024-05-16 13:35
- Avenue Therapeutics press release (NASDAQ:ATXI): Q1 GAAP EPS of $15.40 beats by $24.40.
- As of March 31, 2024, cash and cash equivalents totaled $3.2 million, compared to $1.8 million at December 31, 2023, an increase of $1.4 million.
More on Avenue Therapeutics
- Avenue Therapeutics drops 9% on 1-for-75 reverse split
- Avenue Therapeutics granted extension for Nasdaq compliance
- Seeking Alpha’s Quant Rating on Avenue Therapeutics
- Historical earnings data for Avenue Therapeutics
- Financial information for Avenue Therapeutics
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。